DNA topoisomerase I and II (top1 and top2) are primary targets for cancer chemotherapy. Topo-isomerase poisons act by stabilizing enzyme-linked DNA breaks which can be detected as protein-associated DNA breaks in drug-treated cells (cleavable complexes). However, topoisomerases exist both in normal and cancer cells, and the mechanism(s) of drug selectivity for cancer cells remain(s) poorly understood. The goal of this project is to elucidate the antitumor mechanisms of topoisomerase poisons, and their selectivity for cancer cells. Secondary targets which are different in cancer cells could be used for drug development in association with topoisomerase inhibitors or other DNA damaging agents. We have studied the human colon and ovarian cancer cell lines from the NCI Anticancer Drug Screen to identify the parameters that are best correlated with cytotoxicity and could be used in the clinic to predict and monitor the response to topoisomerase inhibitors. Top1 protein levels appear comparable among cell lines and thus are not predictive, while top1 cleavable complexes are better correlated with cytotoxicity. Cleavable complexes are, however, not always predictive . Using cells lines with comparable cleavable complexes, we demonstrated the importance of the G2 checkpoint and replicon repair, downstream from the cleavable complexes for cytotoxicity. We have shown that the presence of p53 provides a survival advantage against camptothecin cytotoxicity. This may contribute to the selectivity of camptothecins for cancer cells with p53 mutations. We and others have proposed that apoptosis is a key response of cancer cells to chemotherapeutic agents, especially in leukemia cells exposed to topoisomerase inhibitors. We have shown that HL60 cells rapidly upregulate and downregulate cyclin B/cdc2 kinase activity before undergoing apoptosis after DNA damage. We have also set up an in vitro cell-free system to study the biochemical pathways of apoptosis. It appears that human leukemia HL60 cells induce a protease cascade including both ICE/CED3 and serine proteases in response to DNA damage following camptothecin treatment and that the protease(s) activate(s) preexisting nuclear pronuclease(s). New approaches aimed at triggering or suppressing apoptosis may provide new therapeutic strategies and help reduce drug side effects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC006161-13
Application #
2463710
Study Section
Special Emphasis Panel (LMPH)
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1996
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Lee, Hyeong-Min; Clark, Ellen P; Kuijer, M Bram et al. (2018) Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome. Mol Autism 9:45
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Marzi, Laetitia; Agama, Keli; Murai, Junko et al. (2018) Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. Mol Cancer Ther 17:1694-1704
Zhang, Hongliang; Seol, Yeonee; Agama, Keli et al. (2017) Distribution bias and biochemical characterization of TOP1MT single nucleotide variants. Sci Rep 7:8614
Huang, Shar-Yin N; Williams, Jessica S; Arana, Mercedes E et al. (2017) Topoisomerase I-mediated cleavage at unrepaired ribonucleotides generates DNA double-strand breaks. EMBO J 36:361-373
Sloan, Roketa; Huang, Shar-Yin Naomi; Pommier, Yves et al. (2017) Effects of camptothecin or TOP1 overexpression on genetic stability in Saccharomyces cerevisiae. DNA Repair (Amst) 59:69-75
Dalla Rosa, Ilaria; Zhang, Hongliang; Khiati, Salim et al. (2017) Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription. J Biol Chem 292:20162-20172
Marchand, Christophe; Abdelmalak, Monica; Kankanala, Jayakanth et al. (2016) Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2. ACS Chem Biol 11:1925-33
Beck, Daniel E; Lv, Wei; Abdelmalak, Monica et al. (2016) Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons. Bioorg Med Chem 24:1469-79
Riddell, Imogen A; Agama, Keli; Park, Ga Young et al. (2016) Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes. ACS Chem Biol 11:2996-3001

Showing the most recent 10 out of 73 publications